Clinical Study of CD38\CS1 Chimeric Antigen Receptor T Cells in the Treatment of Refractory/Recurrent Multiple Myeloma

NCT06574958 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

ORR,OS,PFS

Interventions

BIOLOGICAL: CD38/CS1 injection

Sponsor

The Second Hospital of Shandong University